Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL)
NCT01530048
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
34
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetes
Healthy
Interventions
DRUG:
insulin aspart
Sponsor
Novo Nordisk A/S